EE200200556A - Midodriini ja/või desglümidodriini sisaldav kontrollitud vabanemisega farmatseutiline kompositsioon - Google Patents
Midodriini ja/või desglümidodriini sisaldav kontrollitud vabanemisega farmatseutiline kompositsioonInfo
- Publication number
- EE200200556A EE200200556A EEP200200556A EEP200200556A EE200200556A EE 200200556 A EE200200556 A EE 200200556A EE P200200556 A EEP200200556 A EE P200200556A EE P200200556 A EEP200200556 A EE P200200556A EE 200200556 A EE200200556 A EE 200200556A
- Authority
- EE
- Estonia
- Prior art keywords
- desglymidodrine
- midodrine
- controlled release
- release pharmaceutical
- pharmaceutical composition
- Prior art date
Links
- VFRCNXKYZVQYLX-UHFFFAOYSA-N deglymidodrine Chemical compound COC1=CC=C(OC)C(C(O)CN)=C1 VFRCNXKYZVQYLX-UHFFFAOYSA-N 0.000 title abstract 6
- PTKSEFOSCHHMPD-SNVBAGLBSA-N 2-amino-n-[(2s)-2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide Chemical compound COC1=CC=C(OC)C([C@H](O)CNC(=O)CN)=C1 PTKSEFOSCHHMPD-SNVBAGLBSA-N 0.000 title abstract 4
- 229960001094 midodrine Drugs 0.000 title abstract 4
- 238000013270 controlled release Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000002207 metabolite Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000036470 plasma concentration Effects 0.000 abstract 2
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 230000002746 orthostatic effect Effects 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nanotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Biotechnology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200000549 | 2000-03-31 | ||
| US20378300P | 2000-05-12 | 2000-05-12 | |
| PCT/DK2001/000213 WO2001074334A1 (en) | 2000-03-31 | 2001-03-29 | Controlled release pharmaceutical composition containing midodrine and/or desglymidodrine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EE200200556A true EE200200556A (et) | 2004-04-15 |
Family
ID=26068806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EEP200200556A EE200200556A (et) | 2000-03-31 | 2001-03-29 | Midodriini ja/või desglümidodriini sisaldav kontrollitud vabanemisega farmatseutiline kompositsioon |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1267841B1 (de) |
| JP (1) | JP2003528909A (de) |
| CN (1) | CN1422150A (de) |
| AT (1) | ATE283036T1 (de) |
| AU (1) | AU2001246388A1 (de) |
| CA (1) | CA2403886A1 (de) |
| DE (1) | DE60107399D1 (de) |
| EE (1) | EE200200556A (de) |
| NO (1) | NO20024673L (de) |
| WO (1) | WO2001074334A1 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2409950A1 (en) * | 2000-05-26 | 2001-11-29 | Nycomed Austria Gmbh | Pharmaceutical compositions comprising desglymidodrine as an active drug substance |
| CA2936740C (en) | 2014-10-31 | 2017-10-10 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
| US11202760B2 (en) * | 2016-09-30 | 2021-12-21 | Xenamed Corp. | Compositions of midodrine and methods of using the same |
| US20190240172A1 (en) * | 2016-10-21 | 2019-08-08 | Cellvertics Co., Ltd. | Pharmaceutical composition for preventing or treating diabetes and/or hyperlipidemia comprising midodrine or pharmaceutically acceptable salt thereof as active ingredient |
| US11013702B2 (en) | 2017-10-10 | 2021-05-25 | Vertice Pharma, Llc | Midodrine hydrochloride oral solution and uses thereof |
| JP7364568B2 (ja) * | 2017-12-22 | 2023-10-18 | ゼナメッド コーポレーション | 持続放出ミドドリン塩酸塩組成物及び使用方法 |
| US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
| KR102151051B1 (ko) * | 2019-01-10 | 2020-09-02 | 고려대학교 산학협력단 | 당뇨병성 백내장 치료 또는 예방용 조성물 |
| WO2022157633A1 (en) * | 2021-01-20 | 2022-07-28 | Cadila Healthcare Limited | Enantiomerically pure desglymidodrine and process for preparation thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3417576A1 (de) * | 1984-05-11 | 1985-11-14 | Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München | Retardformen des alpha-(2,5-dimethoxy-phenyl)-ss-glycinamidoaethanols und verfahren zu ihrer herstellung |
| AT383270B (de) * | 1984-05-15 | 1987-06-10 | Chemie Linz Ag | Verfahren zur herstellung von oralen retardformen des alpha-(2,5-dimethoxy-phenyl)-betaglycinamido|thanols |
| EP0423484B1 (de) * | 1989-10-16 | 1993-11-03 | PCD-Polymere Gesellschaft m.b.H. | Pressling mit retardierter Wirkstofffreisetzung |
-
2001
- 2001-03-29 DE DE60107399T patent/DE60107399D1/de not_active Expired - Lifetime
- 2001-03-29 AT AT01919228T patent/ATE283036T1/de not_active IP Right Cessation
- 2001-03-29 AU AU2001246388A patent/AU2001246388A1/en not_active Abandoned
- 2001-03-29 WO PCT/DK2001/000213 patent/WO2001074334A1/en not_active Ceased
- 2001-03-29 JP JP2001572079A patent/JP2003528909A/ja active Pending
- 2001-03-29 CN CN01807541A patent/CN1422150A/zh active Pending
- 2001-03-29 CA CA002403886A patent/CA2403886A1/en not_active Abandoned
- 2001-03-29 EP EP01919228A patent/EP1267841B1/de not_active Expired - Lifetime
- 2001-03-29 EE EEP200200556A patent/EE200200556A/xx unknown
-
2002
- 2002-09-30 NO NO20024673A patent/NO20024673L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2403886A1 (en) | 2001-10-11 |
| NO20024673D0 (no) | 2002-09-30 |
| JP2003528909A (ja) | 2003-09-30 |
| EP1267841B1 (de) | 2004-11-24 |
| DE60107399D1 (de) | 2004-12-30 |
| EP1267841A1 (de) | 2003-01-02 |
| AU2001246388A1 (en) | 2001-10-15 |
| ATE283036T1 (de) | 2004-12-15 |
| CN1422150A (zh) | 2003-06-04 |
| WO2001074334A1 (en) | 2001-10-11 |
| NO20024673L (no) | 2002-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200201044A1 (ru) | Фармацевтическая композиция с контролируемым высвобождением, содержащая мидодрин и/или десглимидодрин | |
| EA200800161A1 (ru) | Новые фармацевтические композиции с модифицированным высвобождением и способ получения таких композиций | |
| NO20062504L (no) | Sammensetninger og doseringsformer for forbedret absorpsjon | |
| DK1346041T3 (da) | Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom | |
| ES2295609T3 (es) | Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor. | |
| DK1663194T3 (da) | Anvendelse af SAHA til behandling af mesotheliom | |
| BR0315580A (pt) | Derivados de metileno uréia | |
| YU71901A (sh) | NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA | |
| EA200701131A1 (ru) | Гелеобразная препаративная форма капсаициноида и способы её применения | |
| SE0200979D0 (sv) | New compounds | |
| BR0205722A (pt) | Formulação de liberação prolongada e método para o tratamento de um paciente que sofre de dor | |
| ATE267798T1 (de) | Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung | |
| IL178474A0 (en) | Monoclonal antibodies to hepatocyte growth factor and pharmaceutical compositions containing the same | |
| PT1383752E (pt) | 3-piperidinopropiofenonas deuteradas assim como farmacos contendo estes compostos | |
| NO20041059L (no) | Kombinasjon av utvalgte opioder med muskarinantagonister for behandling av urininkontinens | |
| EP1383540A4 (de) | Methoden und pharmazeutische zusammensetzungen zur wundheilung | |
| EE200200556A (et) | Midodriini ja/või desglümidodriini sisaldav kontrollitud vabanemisega farmatseutiline kompositsioon | |
| ATE464878T1 (de) | Pharmazeutische zusammensetzung zur nasalen anwendung von fentanyl | |
| EA200700777A1 (ru) | Содержащие октенидин таблетки для рассасывания, предназначенные для лечения воспалительных заболеваний полости рта и глотки | |
| EP1262197A3 (de) | Kombinationstherapie zur Behandlung von Schlafstörungen, Schlaflosigkeit inbegriffen | |
| EA200501223A1 (ru) | Терапевтическая система, содержащая амоксициллин и клавулановую кислоту | |
| GEP201606538B (en) | Preoperative treatment of post operative pain | |
| SE0102887D0 (sv) | New formulation | |
| PT1337246E (pt) | Utilizacao de compostos de 6-dimetilaminometil-1-fenilciclohexano para terapia da incontinencia urinaria | |
| WO2002053099A3 (en) | Methods and compositions for treating periodontal disease |